Management of Elevated Blasts in Cell Differential

Diagnostic Evaluation

The American Society of Hematology recommends complete bone marrow aspiration and biopsy to quantify blast percentage accurately and obtain material for comprehensive analysis 1, 2
Cytogenetic analysis on bone marrow cells is necessary to identify chromosomal abnormalities, such as t(9;22), complex karyotype, del(5q), trisomy 8, etc. 1, 2
Molecular studies, including BCR::ABL1 fusion, FLT3, NPM1, IDH1/2, ASXL1, and other mutations via next-generation sequencing, are essential for diagnosis 1, 3
Flow cytometry for immunophenotyping is crucial to determine lineage (myeloid vs lymphoid) and identify aberrant antigen expression 1, 2, 3

For patients with ≥20% blasts, the National Comprehensive Cancer Network recommends immediate initiation of induction chemotherapy after stabilization of hyperleukocytosis and tumor lysis syndrome 2, 5
The European LeukemiaNet recommends allogeneic hematopoietic stem cell transplantation as the only curative option for patients with 10-19% bone marrow blasts 6, 7
For patients with chronic myeloid leukemia, the International Chronic Myeloid Leukemia Foundation recommends tyrosine kinase inhibitor therapy, with blast percentage determining CML phase classification 1, 2

The American College of Physicians recommends standard "7+3" induction chemotherapy with cytarabine and daunorubicin or idarubicin for acute leukemia patients <60 years old 3
For acute leukemia patients ≥60 years old, the International Society of Geriatric Oncology recommends hypomethylating agents, such as azacitidine or decitabine, for unfit patients 3
The European Society for Medical Oncology recommends azacitidine as first-line therapy for transplant-ineligible patients with high-risk myelodysplastic syndrome 6, 7

The American Society of Clinical Oncology recommends daily complete blood counts to assess for cytopenias and infection risk, as well as frequent electrolyte monitoring for tumor lysis syndrome 3, 5, 7
Bone marrow reassessment is necessary at day 14-21 for acute leukemia, or every 1-2 cycles for MDS/hypomethylating therapy 5, 3, 7